AU2008228303B2 - Substituted pyrimidodiazepines useful as PLK1 inhibitors - Google Patents

Substituted pyrimidodiazepines useful as PLK1 inhibitors Download PDF

Info

Publication number
AU2008228303B2
AU2008228303B2 AU2008228303A AU2008228303A AU2008228303B2 AU 2008228303 B2 AU2008228303 B2 AU 2008228303B2 AU 2008228303 A AU2008228303 A AU 2008228303A AU 2008228303 A AU2008228303 A AU 2008228303A AU 2008228303 B2 AU2008228303 B2 AU 2008228303B2
Authority
AU
Australia
Prior art keywords
methyl
mole
tetrahydro
pyrimido
diazepin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008228303A
Other languages
English (en)
Other versions
AU2008228303A1 (en
Inventor
Jianping Cai
Shaoqing Chen
Xin-Jie Chu
Kang Le
Kin-Chun Thomas Luk
Peter Michael Wovkulich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39415299&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2008228303(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2008228303A1 publication Critical patent/AU2008228303A1/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: F. HOFFMANN-LA ROCHE AG
Application granted granted Critical
Publication of AU2008228303B2 publication Critical patent/AU2008228303B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2008228303A 2007-03-22 2008-03-11 Substituted pyrimidodiazepines useful as PLK1 inhibitors Ceased AU2008228303B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91935807P 2007-03-22 2007-03-22
US60/919,358 2007-03-22
PCT/EP2008/052847 WO2008113711A1 (en) 2007-03-22 2008-03-11 Substituted pyrimidodiazepines useful as plk1 inhibitors

Publications (2)

Publication Number Publication Date
AU2008228303A1 AU2008228303A1 (en) 2008-09-25
AU2008228303B2 true AU2008228303B2 (en) 2012-04-19

Family

ID=39415299

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008228303A Ceased AU2008228303B2 (en) 2007-03-22 2008-03-11 Substituted pyrimidodiazepines useful as PLK1 inhibitors

Country Status (23)

Country Link
US (1) US7517873B2 (cg-RX-API-DMAC7.html)
EP (1) EP2139892B1 (cg-RX-API-DMAC7.html)
JP (1) JP5087640B2 (cg-RX-API-DMAC7.html)
KR (1) KR101157848B1 (cg-RX-API-DMAC7.html)
CN (2) CN102746175B (cg-RX-API-DMAC7.html)
AR (1) AR065794A1 (cg-RX-API-DMAC7.html)
AT (1) ATE524472T1 (cg-RX-API-DMAC7.html)
AU (1) AU2008228303B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0809088A2 (cg-RX-API-DMAC7.html)
CA (1) CA2680757A1 (cg-RX-API-DMAC7.html)
CL (1) CL2008000785A1 (cg-RX-API-DMAC7.html)
CY (1) CY1112102T1 (cg-RX-API-DMAC7.html)
DK (1) DK2139892T3 (cg-RX-API-DMAC7.html)
ES (1) ES2371832T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20110807T1 (cg-RX-API-DMAC7.html)
IL (1) IL200617A (cg-RX-API-DMAC7.html)
MX (1) MX2009010034A (cg-RX-API-DMAC7.html)
PE (1) PE20120495A1 (cg-RX-API-DMAC7.html)
PL (1) PL2139892T3 (cg-RX-API-DMAC7.html)
PT (1) PT2139892E (cg-RX-API-DMAC7.html)
SI (1) SI2139892T1 (cg-RX-API-DMAC7.html)
TW (1) TWI363629B (cg-RX-API-DMAC7.html)
WO (1) WO2008113711A1 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009023269A2 (en) * 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated 4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5h-pyrimido [4, 5-b[1, 4] diazepin-2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases plk1 to plk4 for the treatment of proliferative diseases
AU2008304417B2 (en) * 2007-09-25 2013-07-18 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
CA2700979C (en) * 2007-09-28 2017-06-20 Cyclacel Limited Pyrimidine derivatives as protein kinase inhibitors
US20090291938A1 (en) * 2007-11-19 2009-11-26 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為vap-1抑制劑之用途
EP2303889A1 (en) * 2008-06-18 2011-04-06 F. Hoffmann-La Roche AG Halo-substituted pyrimidodiazepines as plkl inhibitors
CN103497192B (zh) 2008-12-09 2015-09-23 吉里德科学公司 Toll样受体调节剂
EP3828185B1 (en) 2009-01-06 2024-11-20 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
PL2442809T3 (pl) 2009-06-17 2017-02-28 Vertex Pharmaceuticals Incorporated Inhibitory replikacji wirusów grypy
JP5763077B2 (ja) 2009-09-14 2015-08-12 ギリアード サイエンシーズ, インコーポレイテッド トール様受容体のモジュレーター
AU2011343642A1 (en) 2010-12-16 2013-05-02 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
WO2014145909A2 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders
EP3024327B1 (en) 2013-07-25 2019-09-04 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
TWI652014B (zh) * 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
EP3421468B1 (en) 2013-11-13 2020-11-04 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
LT3068776T (lt) 2013-11-13 2019-08-12 Vertex Pharmaceuticals Incorporated Gripo virusų replikacijos inhibitoriai
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
RU2016134947A (ru) 2014-01-31 2018-03-01 Дана-Фарбер Кансер Институт, Инк. Производные диаминопиримидин бензолсульфона и их применение
JP6522732B2 (ja) 2014-07-11 2019-05-29 ギリアード サイエンシーズ, インコーポレイテッド Hivを治療するためのトール様受容体の調節因子
WO2016022902A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
KR20190125537A (ko) 2014-09-16 2019-11-06 길리애드 사이언시즈, 인코포레이티드 톨-유사 수용체 조정제의 고체 형태
JP6373490B2 (ja) 2014-09-16 2018-08-15 ギリアード サイエンシーズ, インコーポレイテッド Toll様受容体モジュレーターを調製する方法
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated インフルエンザウイルスの複製の阻害剤を調製する方法
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CR20180199A (es) 2015-09-11 2018-05-25 Dana Farber Cancer Inst Inc Acetamida tienotriazolodiazepinas y usos de las mismas
BR112018004618A2 (pt) 2015-09-11 2018-09-25 Dana-Farber Cancer Institute, Inc. ciano tienotriazoldiazepinas e usos das mesmas
BR112018009798A8 (pt) 2015-11-25 2019-02-26 Dana Farber Cancer Inst Inc inibidores de bromodomínio bivalentes e usos dos mesmos
JP6968819B2 (ja) * 2016-04-07 2021-11-17 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッドDana−Farber Cancer Institute, Inc. ピリミド−ジアゼピノンキナーゼ骨格化合物およびpi3k媒介性障害の治療方法
EP4034132A4 (en) * 2019-09-27 2023-10-11 Dana-Farber Cancer Institute, Inc. Erk5 degraders as therapeutics in cancer and inflammatory diseases
US20230158158A1 (en) * 2020-03-27 2023-05-25 Uppthera Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1
WO2022145989A1 (ko) * 2020-12-31 2022-07-07 (주) 업테라 선택적 plk1 억제제로서의 피리미도디아제핀 유도체
WO2023018237A1 (en) * 2021-08-10 2023-02-16 Uppthera, Inc. Novel plk1 degradation inducing compound
GB202313514D0 (en) 2023-09-05 2023-10-18 Cambridge Entpr Ltd Treatment of inflammatory diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL354241A1 (en) * 1999-09-17 2003-12-29 Abbott Gmbh & Co.Kgabbott Gmbh & Co.Kg Kinase inhibitors as therapeutic agents
WO2003020722A1 (de) * 2001-09-04 2003-03-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
NZ570530A (en) * 2006-02-14 2011-09-30 Vertex Pharma Pharmaceutical compositions comprising 6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4)diazepine derivatives
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
JP2010521514A (ja) 2010-06-24
EP2139892A1 (en) 2010-01-06
PT2139892E (pt) 2011-11-21
SI2139892T1 (sl) 2011-12-30
ATE524472T1 (de) 2011-09-15
EP2139892B1 (en) 2011-09-14
PE20120495A1 (es) 2012-05-12
PL2139892T3 (pl) 2012-03-30
AR065794A1 (es) 2009-07-01
TW200843781A (en) 2008-11-16
DK2139892T3 (da) 2011-12-12
US20080234255A1 (en) 2008-09-25
CY1112102T1 (el) 2015-11-04
CN101636399A (zh) 2010-01-27
IL200617A0 (en) 2010-05-17
BRPI0809088A2 (pt) 2014-09-09
ES2371832T3 (es) 2012-01-10
CN101636399B (zh) 2012-04-18
CA2680757A1 (en) 2008-09-25
JP5087640B2 (ja) 2012-12-05
KR20090119913A (ko) 2009-11-20
KR101157848B1 (ko) 2012-07-11
TWI363629B (en) 2012-05-11
HRP20110807T1 (hr) 2011-12-31
MX2009010034A (es) 2009-10-12
CN102746175B (zh) 2014-01-15
CL2008000785A1 (es) 2009-03-27
HK1139936A1 (en) 2010-09-30
IL200617A (en) 2014-02-27
WO2008113711A1 (en) 2008-09-25
AU2008228303A1 (en) 2008-09-25
US7517873B2 (en) 2009-04-14
CN102746175A (zh) 2012-10-24

Similar Documents

Publication Publication Date Title
AU2008228303B2 (en) Substituted pyrimidodiazepines useful as PLK1 inhibitors
CN114555593A (zh) 作为parg抑制剂的4-取代的吲哚和吲唑磺酰胺衍生物
TWI534145B (zh) 四氫吡啶并嘧啶衍生物
US11230551B2 (en) Deuterated analogs of MK2 inhibitors and uses thereof
AU2018285131B2 (en) Heteroaromatic compounds as Vanin inhibitors
AU2009294660A1 (en) New compounds I
EP3768272B1 (en) Jak inhibitors
US20170105994A1 (en) Certain protein kinase inhibitors
EP2112150A1 (en) Improved raf inhibitors
KR20240130693A (ko) Cdk9 억제제 및 이의 용도
US20190359618A1 (en) Compounds for inhibiting lrrk2 kinase activity
NZ568014A (en) Substituted bicyclic pyrimidone derivatives
TWI875911B (zh) Bruton酪胺酸激酶(BTK)抑制劑
AU2021270672A1 (en) Fused aza-heterocyclic amide compound and use thereof
AU2021410926A9 (en) Tetrahydrothienopyrimidinesulfonamide compounds
MX2010011136A (es) Derivados de pirrolo [2,3-d] pirimidin-2-il-amina como inhibidores pkc-theta.
HK1139936B (en) Substituted pyrimidodiazepines useful as plk1 inhibitors
HK1218119B (en) Certain protein kinase inhibitors
HK1219071B (en) New compounds
HK1219071A1 (en) New compound

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER APPLICANT(S): F. HOFFMANN-LA ROCHE AG

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired